1. Amgen to acquire Oxford spinout Dark Blue, tucking in a preclinical cancer drug  Endpoints News
  2. Amgen swoops on UK cancer biotech in deal worth up to $840mn  Financial Times
  3. AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE  PR Newswire
  4. Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs  Fierce Biotech
  5. Recon: Amgen to acquire Dark Blue for $480M; CDC slashes recommendations for childhood vaccines  Regulatory Affairs Professionals Society | RAPS